ASIA PACIFIC CYSTIC FIBROSIS THERAPEUTICS MARKET FORECAST 2020-2028

  • You are here:
  • Home
  • Reports
  • ASIA PACIFIC CYSTIC FIBROSIS THERAPEUTICS MARKET FORECAST 2020-2028

ASIA PACIFIC CYSTIC FIBROSIS THERAPEUTICS MARKET FORECAST 2020-2028

The Asia Pacific cystic fibrosis market is evaluated to register a CAGR of 9.58% over the forecast period, 2020-2028. The advancements in the cystic fibrosis treatment are influencing the market growth in the region. In order to understand the cystic fibrosis market of the Asia Pacific further, the region is divided into India, South Korea, Japan, Thailand, Australia & New Zealand, Vietnam, China, Indonesia,  and the rest of Asia Pacific. In China, the CF patients are severely under-recognized with a high rate of misdiagnosis and missed diagnosis.

ASIA PACIFIC CYSTIC FIBROSIS THERAPEUTICS MARKET FORECAST 2020-2028

Request free sample

The Asia Pacific cystic fibrosis market is evaluated to register a CAGR of 9.58% over the forecast period, 2020-2028. The advancements in the cystic fibrosis treatment are influencing the market growth in the region.

In order to understand the cystic fibrosis market of the Asia Pacific further, the region is divided into India, South Korea, Japan, Thailand, Australia & New Zealand, Vietnam, China, Indonesia,  and the rest of Asia Pacific. In China, the CF patients are severely under-recognized with a high rate of misdiagnosis and missed diagnosis. At present, treatment strategies for CF mainly focus on preventing infection and providing nutritional support, therefore promoting the market in China. In Japan, the market is expected to grow at a steady rate, due to lower incidences of the disease in the region. In India, it is difficult to manage cystic fibrosis due to an inadequate number of trained manpower, high cost, and limited availability of pharmacologic agents. CF does not occur in India. However, there is a need to develop diagnostic facilities, create awareness among pediatricians, and manage protocols based on locally available resources.

According to SCIMEX Australia, an Australian-led trial has found out that the addition of a new drug called VX-445 to two existing treatments drastically improved the lung function of patients with cystic fibrosis. This new drug helped patients who had the most common gene defect. In New Zealand, CF is the most common genetic condition that limits the lifespan. There are over 500 children and adults living with CF in New Zealand. The new development in the field of CF in Australia and the prevalence of the disease in New Zealand is expected to accelerate market growth.

Pharmaxis Ltd, is an Australian pharmaceutical research company, and a global leader in drug development for inflammation and fibrotic diseases. It markets its products in the US, Europe, Australia, and Southeast Asia.

To request a free sample copy of this report, please complete the form below :

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

  1. RESEARCH SCOPE & METHODOLOGY
    • STUDY OBJECTIVES
    • SCOPE OF STUDY
    • METHODOLOGY
    • ASSUMPTIONS & LIMITATIONS
  2. EXECUTIVE SUMMARY
    • MARKET SIZE & ESTIMATES
    • MARKET OVERVIEW
  3. MARKET DYNAMICS
    • MARKET DEFINITION
    • KEY DRIVERS
      • ADVANCEMENTS IN THE CYSTIC FIBROSIS THERAPEUTICS TREATMENT
      • INCREASING INCIDENCE OF CYSTIC FIBROSIS (CF)
      • RISE IN THE R&D OF NOVEL CYSTIC FIBROSIS THERAPEUTICS
    • KEY RESTRAINTS
      • STRINGENT REGULATION
      • LOW AWARENESS AMONG DEVELOPING ECONOMIES
  1. KEY ANALYTICS
    • PORTER’S FIVE FORCE ANALYSIS
      • THREAT OF NEW ENTRY
      • THREAT OF SUBSTITUTION
      • BUYER’S POWER
      • SUPPLIER’S POWER
      • COMPETITIVE RIVALRY
    • PESTEL ANALYSIS
    • OPPORTUNITY MATRIX
    • VENDOR LANDSCAPE
    • KEY INVESTMENT INSIGHTS
  2. MARKET BY ROUTE OF ADMINISTRATION
    • INHALE
    • ORAL
  3. MARKET BY DRUG CLASS
    • CFTR MODULATORS
    • BRONCHODILATORS
    • MUCOLYTIC
    • PANCREATIC ENZYME SUPPLEMENTS
  4. GEOGRAPHICAL ANALYSIS
    • ASIA PACIFIC
      • CHINA
      • JAPAN
      • INDIA
      • AUSTRALIA & NEW ZEALAND
      • SOUTH KOREA
      • THAILAND
      • INDONESIA
      • VIETNAM
      • REST OF ASIA PACIFIC
  1. COMPANY PROFILES
    • ABBOTT LABORATORIES
    • ABBVIE INC
    • AGILENT TECHNOLOGIES INC
    • ALLERGAN PLC
    • HOFFMANN-LA ROCHE
    • GILEAD SCIENCES INC
    • GLAXOSMITHKLINE PLC
    • JOHNSON & JOHNSON
    • MYLAN N.V
    • NOVARTIS AG
    • PERKINELMER
    • PFIZER INC
    • PHARMAXIS LTD
    • TEVA PHARMACEUTICAL INDUSTRIES LTD
    • VERTEX PHARMACEUTICALS INCORPORATED

TABLE LIST

TABLE 1: MARKET SNAPSHOT – VETERINARY VACCINE

TABLE 2: ASIA PACIFIC CYSTIC FIBROSIS THERAPEUTICS, BY ROUTE OF ADMINISTRATION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 3: ASIA PACIFIC CYSTIC FIBROSIS THERAPEUTICS, BY ROUTE OF ADMINISTRATION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 4: ASIA PACIFIC INHALE MARKET, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 5: ASIA PACIFIC INHALE MARKET, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 6: ASIA PACIFIC ORAL MARKET, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 7: ASIA PACIFIC ORAL MARKET, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 8: ASIA PACIFIC CYSTIC FIBROSIS THERAPEUTICS, BY DRUG CLASS, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 9: ASIA PACIFIC CYSTIC FIBROSIS THERAPEUTICS, BY DRUG CLASS, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 10: ASIA PACIFIC CFTR MODULATORS MARKET, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 11: LIST OF CFTR MODULATORS GENERIC AND BRAND NAME

TABLE 12: ASIA PACIFIC CFTR MODULATORS MARKET, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 13: ASIA PACIFIC BRONCHODILATORS MARKET, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 14: LIST OF BRONCHODILATORS GENERIC AND BRAND NAME

TABLE 15: ASIA PACIFIC BRONCHODILATORS MARKET, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 16: ASIA PACIFIC MUCOLYTIC MARKET, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 17: LIST OF MUCOLYTICS GENERIC AND BRAND NAME

TABLE 18: ASIA PACIFIC MUCOLYTIC MARKET, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 19: ASIA PACIFIC PANCREATIC ENZYME SUPPLEMENTS MARKET, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 20: ASIA PACIFIC PANCREATIC ENZYME SUPPLEMENTS MARKET, FORECAST YEARS, 2020-2028 (IN $ MILLION)

TABLE 21: ASIA PACIFIC CYSTIC FIBROSIS THERAPEUTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 22: ASIA PACIFIC CYSTIC FIBROSIS THERAPEUTICS MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)

FIGURES LIST 

FIGURE 1: PORTER’S FIVE FORCES ANALYSIS

FIGURE 2: OPPORTUNITY MATRIX

FIGURE 3: VENDOR LANDSCAPE

FIGURE 4: KEY INVESTMENT INSIGHTS

FIGURE 5: ASIA PACIFIC CYSTIC FIBROSIS THERAPEUTICS, BY ROUTE OF ADMINISTRATION, IN 2019

FIGURE 6: ASIA PACIFIC CYSTIC FIBROSIS THERAPEUTICS MARKET, BY INHALE, 2020-2028 (IN $ MILLION)

FIGURE 7: ASIA PACIFIC CYSTIC FIBROSIS THERAPEUTICS MARKET, BY ORAL, 2020-2028 (IN $ MILLION)

FIGURE 8: ASIA PACIFIC CYSTIC FIBROSIS THERAPEUTICS, BY DRUG CLASS, IN 2019

FIGURE 9: ASIA PACIFIC CYSTIC FIBROSIS THERAPEUTICS MARKET, BY CFTR MODULATORS, 2020-2028 (IN $ MILLION)

FIGURE 10: ASIA PACIFIC CYSTIC FIBROSIS THERAPEUTICS MARKET, BY BRONCHODILATORS, 2020-2028 (IN $ MILLION)

FIGURE 11: ASIA PACIFIC CYSTIC FIBROSIS THERAPEUTICS MARKET, BY MUCOLYTIC, 2020-2028 (IN $ MILLION)

FIGURE 12: ASIA PACIFIC CYSTIC FIBROSIS THERAPEUTICS MARKET, BY PANCREATIC ENZYME SUPPLEMENTS, 2020-2028 (IN $ MILLION)

FIGURE 13: ASIA PACIFIC CYSTIC FIBROSIS THERAPEUTICS MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)

FIGURE 14: CHINA CYSTIC FIBROSIS THERAPEUTICS, 2020-2028 (IN $ MILLION)

FIGURE 15: JAPAN CYSTIC FIBROSIS THERAPEUTICS, 2020-2028 (IN $ MILLION)

FIGURE 16: INDIA CYSTIC FIBROSIS THERAPEUTICS, 2020-2028 (IN $ MILLION)

FIGURE 17: AUSTRALIA & NEW ZEALAND CYSTIC FIBROSIS THERAPEUTICS, 2020-2028 (IN $ MILLION)

FIGURE 18: SOUTH KOREA CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)

FIGURE 19: THAILAND CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)

FIGURE 20: INDONESIA CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)

FIGURE 21: VIETNAM CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)

FIGURE 22: REST OF ASIA PACIFIC CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)

  1. GEOGRAPHICAL ANALYSIS
    • ASIA PACIFIC
      • CHINA
      • JAPAN
      • INDIA
      • AUSTRALIA & NEW ZEALAND
      • SOUTH KOREA
      • THAILAND
      • INDONESIA
      • VIETNAM
      • REST OF ASIA PACIFIC
  1. MARKET BY ROUTE OF ADMINISTRATION
    • INHALE
    • ORAL
  2. MARKET BY DRUG CLASS
    • CFTR MODULATORS
    • BRONCHODILATORS
    • MUCOLYTIC
    • PANCREATIC ENZYME SUPPLEMENTS

To request a free sample copy of this report, please complete the form below :

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

Choose License Type

Buy Now